Strategic advisory across the full deal lifecycle.
PharmaSync runs cross-border life-science transactions end to end – from the first confidential conversation to a signed close. Buy-side or sell-side, single asset or whole platform, our partners stay on the file from thesis to term sheet.
Four mandates, one integrated desk.
Most engagements begin with a single objective and grow as trust does. Each service is scoped on its own, yet draws on the same network, the same diligence rigor, and the same partners across the corridor.
In-Licensing
Define a search thesis, source external innovation across global pipelines, validate the asset package, and negotiate rights that fit your strategy.
View ->Out-Licensing
Position a differentiated program for the right strategic buyers, prepare a defensible package, map qualified counterparties, and run terms to close.
View ->Strategic Partnerships
Structure development, manufacturing, and commercialization alliances that share risk and reward across borders without losing focus.
View ->NewCo Formation
Carve assets into independent entities, syndicate the capital to back them, and design governance that lets a focused team move fast.
View ->A disciplined path from first call to close.
Every mandate runs the same four phases. The pace varies; the rigor does not.
Frame the mandate
Under NDA, we define the objective, the boundaries, and what a good outcome looks like – before any counterparty is approached.
Source & qualify
We work the network to surface assets or buyers that fit, then filter hard so only credible, motivated counterparties reach your desk.
Diligence & structure
Scientific, commercial, and legal review run in parallel while we shape a deal structure that holds up across jurisdictions.
Negotiate & close
Partners lead the negotiation to term sheet and through signing, with continuity from the people who opened the file.
Where our network runs deepest.
We are modality-agnostic, from small molecule to cell & gene. These are the areas where our relationships, diligence depth, and deal history are strongest.
Oncology
ADCs, bispecifics, and targeted small molecules across solid and heme programs.
Immunology
Autoimmune, inflammation, and next-generation immunomodulators.
Metabolic
GLP-1 combinations, NASH, and broader cardiometabolic assets.
Cell & Gene
CAR-T, allogeneic platforms, and in-vivo gene therapy.
CNS
Neurodegeneration, psychiatry, and rare neurological indications.
Rare Disease
Orphan and ultra-rare programs with focused patient populations.
Devices & Dx
Medical devices, diagnostics, and companion diagnostics.
Digital Health
AI-led discovery, clinical-trial technology, and digital therapeutics.